An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors

Trial Profile

An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Lenvatinib (Primary) ; Midazolam
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 16 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 30 Dec 2017.
    • 24 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2018.
    • 13 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top